[ad_1]
Precision medication participant harnesses distinctive genetic insights to focus on persistent kidney illness and past.
Precision medication firm Maze Therapeutics has filed for an preliminary public providing (IPO) with the Securities and Alternate Fee. The San Francisco-based firm focuses on growing novel, small molecule precision medicines for renal, cardiovascular and associated metabolic ailments, together with weight problems.
Based in 2017, Maze firm reportedly plans to checklist on the Nasdaq below the ticker image MAZE in what may develop into the primary biotech IPO of 2025. In accordance with Reuters, the corporate reported a revenue of $9.03 million for the 9 months ended September 30, 2024, in comparison with a lack of $73.84 million in the identical interval the earlier 12 months.
Previous to the IPO submitting, Maze just lately accomplished an oversubscribed $115 million Series D financing round, geared toward advancing its kidney illness candidates.
“Maze has exhibited spectacular productiveness using its precision medicine-focused platform and variant functionalization method,” stated Dr James Brush of Frazier Life Sciences, which invested within the Collection D spherical. “We imagine Maze is properly positioned to handle key drivers of illness for sufferers residing with CKD, AKD, FSGS, PKU and different metabolic ailments.”
Maze leverages its proprietary platform to determine and characterize genetic variants in ailments, linking them to organic pathways that drive illness in particular affected person teams. The corporate says its platform integrates human genetics knowledge with practical genomics instruments and knowledge science expertise to determine pharmacologically related gene-disease associations. This accelerates its growth of small molecule precision medicines designed to mimic the results of uncommon, naturally occurring, protecting genetic variants.
Maze’s most superior program is an oral, small molecule inhibitor focusing on apolipoprotein L1 (APOL1) for the remedy of APOL1 kidney illness, which just lately entered a Part 2 trial. One other candidate in Maze’s pipeline is an oral drug focusing on persistent kidney illness, which entered Part 1 trials in September.
[ad_2]
Source link
